BBH - VanEck Vectors Biotech ETF
| Previous Close | 117.39 |
| Open | 117.12 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 116.38 - 117.35 |
| 52 Week Range | 113.36 - 136.83 |
| Volume | 14,705 |
| Avg. Volume | 44,298 |
| Net Assets | 438.65M |
| NAV | 120.29 |
| PE Ratio (TTM) | N/A |
| Yield | 0.57% |
| YTD Return | -3.41% |
| Beta (3y) | 1.33 |
| Expense Ratio (net) | 0.35% |
| Inception Date | 2011-12-20 |
- CNBC Videos•7 months ago
Investors getting back into M&A : York Capital co-CEO
Daniel Schwartz, York Capital Management co-CEO, weighs in on the strength of the M&A market and where he sees the biggest opportunities, including biotechnology and the telecom industry.
- CNBC Videos•9 months ago
Celgene CEO: Time to think about health care in a differe...
Mark Alles, Celgene CEO, talks about the importance of forming a partnership between innovators and insurance companies in order to provide patients with access to precision medicines.
- CNBC Videos•9 months ago
Celgene CEO: Precision medicine targeting metabolic drive...
Mark Alles, Celgene CEO, talks about gaining FDA approval for a drug that targets a lethal form of leukemia and discusses the importance of getting patients access to precision medicines.
- Market Realist•28 days ago
What’s Ionis Pharmaceuticals’ Valuation in March 2018?
How Ionis Pharmaceuticals Is Positioned in 2018A look at Ionis Pharmaceuticals
- Market Realist•last month
A Look at Incyte’s Valuation in March 2018
Who’s Watching Incyte Corporation in March 2018?Incyte Corporation
- Motley Fool•last month
The 4 Top Biotech ETFs
Investing in biotechnology has been very lucrative lately, and these funds can help you tap into the industry's success.
- Market Realist•2 months ago
Gilead Sciences: Analysts’ Estimates after 4Q17
What Could Drive Gilead Sciences' Valuation in March?
- InvestorPlace•3 months ago
4 ETFs Set to Surge Amid Q4 Earnings
The fourth-quarter earnings season is expected to be strong, with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter. The S&P 500 index is anticipated to see earnings growth of 9.2% and revenue growth of 7%. The market is also at record levels, scaling series of highs at the start of the year.Source: Shutterstock
- Market Realist•3 months ago
A Look at Ionis’s 3Q17 Revenue Stream
What's the Word on Ionis Pharmaceuticals This January?
- Market Realist•3 months ago
How Was Incyte’s Revenue Stream in 3Q17?
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.
- Business Wire•4 months ago
VanEck Announces Yearend Distributions for VanEck Vectors Equity ETFs
VanEck announced today the following 2017 annual distributions per share for its VanEck Vectors® equity exchange-traded funds.
- Business Wire•5 months ago
VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs
VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.
- Market Realist•7 months ago
Benefitting from IBB’s Lower Expense Ratio
The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.
- Market Realist•7 months ago
How Gilead’s HIV and HBV Portfolios Performed in 2Q17
Gilead Sciences' (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver diseases, oncology, cardiovascular, inflammation, respiratory, and others.
- Market Realist•8 months ago
How Akcea Therapeutics’ Volanesorsen Performed in 2Q17
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug designed to reduce apoC-III protein production and lower triglycerides for patients with dyslipidemia.
- Market Realist•8 months ago
Understanding Incyte’s 2Q17 Revenue Stream
Incyte's 2Q17 revenue growth was driven by the increased demand for Jakafi.
- Market Realist•8 months ago
What’s Allergan’s Valuation after 2Q17 Earnings?
Allergan reported an 8.8% increase in its 2Q17 revenues to $4.0 billion as compared to $3.7 billion in 2Q16.
- Market Realist•9 months ago
Analysts’ Recommendations for Regeneron in July 2017
In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study.
- Zacks•9 months ago
3 ETFs to Watch Out for on Biotech Earnings
Major players in the biotech space reported their second quarter 2017 results.
- Zacks•9 months ago
3 ETFs Loaded with Positive ESP Stocks
Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank #1, 2 or 3 would lead to profits in investor portfolios.
- Market Realist•9 months ago
Inside Allergan’s Developments in 2Q17
Allergan (AGN) is a US-based pharmaceuticals company that deals in over-the-counter products, eye care products, and aesthetics products.
- Market Realist•9 months ago
A Look at Allergan’s Performance in 2Q17
Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on generic and specialty pharmaceutical products. The company has divided its business into three segments: ...
- Forbes•10 months ago
Biotech Stocks Are Soaring, Todd Hagopian Leads The Way
Todd Hagopian’s Biotech Fund is up over 30% as many of his stock picks have taken off after President Trump and Senate Republicans turned their attention to healthcare.
